Treatment of drug-induced exogenous psychosis in Parkinsonism with clozapine and fluperlapine

@article{Scholz2004TreatmentOD,
  title={Treatment of drug-induced exogenous psychosis in Parkinsonism with clozapine and fluperlapine},
  author={Erich Scholz and Johannes Dichgans},
  journal={European archives of psychiatry and neurological sciences},
  year={2004},
  volume={235},
  pages={60-64}
}
  • E. Scholz, J. Dichgans
  • Published 2004
  • Psychology, Medicine
  • European archives of psychiatry and neurological sciences
SummaryA total of 13 patients with drug-induced psychosis in Parkinson's disease were treated with two non-classical neuroleptics-clozapine and fluperlapine. Patients mainly complained about severe hallucinatory symptoms and different degrees of paranoid delusions. Complete relief was observed in 8 patients, moderate improvement in 3 and no effects in 2. Parkinsonian disability did not increase under neuroleptic medication with clozapine and fluperlapine, but could be ameliorated by additional… 
Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs
  • K. Ikeguchi, A. Kuroda
  • Psychology, Medicine
    European Archives of Psychiatry and Clinical Neuroscience
  • 2005
TLDR
The results suggest that serotonin antagonism at 5-HT2 receptors may not only play an important role in the treatment of drug-induced psychosis in PD, but may also ameliorate the symptoms of parkinsonism.
Treating Hallucinations and Delusions Associated With Parkinson’s Disease Psychosis
TLDR
Pimavanserin, a 5-HT2A/C receptor inverse agonist with no other receptor activity, has shown efficacy and tolerability and is now FDA approved for PDP treatment and research into novel targets is ongoing.
Clozapine: neuroleptic-induced EPS and tardive dyskinesia
  • D. Casey
  • Psychology, Medicine
    Psychopharmacology
  • 2004
TLDR
Preliminary data suggest clozapine has mild antiparkinsonian effects as well as efficacy in controlling dopamine agonist-induced psychosis without aggravating parkinsonism.
Efficacy of Novel Antipsychotic Drugs in Treatment-Refractory Schizophrenia
TLDR
The social function and quality of life of patients with schizophrenia treated with typical neuroleptics is generally poor, and low employment and marital rates are evidence for the limitations of current therapy.
Pharmacological interventions for psychosis in Parkinson’s disease patients
  • J. Friedman
  • Psychology, Medicine
    Expert opinion on pharmacotherapy
  • 2018
TLDR
This article reviews the therapeutic approaches of this syndrome focusing on drug treatments used once contributory factors have been removed, including a review of the evidence supporting the use of clozapine and, most recently, pimavanserin, the first drug with antipsychotic efficacy that has no effect on dopamine.
Parkinson Disease Psychosis: Update
  • J. Friedman
  • Psychology, Medicine
    Behavioural neurology
  • 2013
TLDR
Only clozapine has level A evidence to support its use in PD patients with psychosis (PDP), whether demented or not, and other antipsychotic drugs have been reported to worsen motor function and data on the effectiveness of cholinesterase inhibitors is limited.
Psychosis in Parkinson's disease: therapeutic options.
TLDR
There is a considerable need to further study the existing drugs and explore other pharmacotherapies in Parkinson's disease psychosis to ensure sound methodological quality and control for confounding variables to provide results that could be used reliably in clinical practice.
Atypical Antipsychotics in Parkinson-Sensitive Populations
TLDR
The data is reviewed and the differences that these four drugs have on motor function are highlighted and the challenges in evaluating the available data on the motor effects of AA are emphasized, especially on the non-PD elderly and cognitively impaired population.
Treatment of Parkinson’s Disease Psychosis
TLDR
Present reviews of evidence-based medicine suggest that low doses of clozapine can provide benefit without worsening PD motor symptoms and pimavanserin should be considered first-line treatment of PDP at this time.
Atypical Antipsychotic Drugs in the Treatment of Parkinson’s Disease
  • J. Friedman
  • Psychology, Medicine
    Journal of pharmacy practice
  • 2011
TLDR
Double blind, placebo controlled trials (DBPCT) have shown that clozapine is effective at controlling the psychotic symptoms at doses far below those used in schizophrenia, without worsening motor function, even improving tremor, while DBPCT have demonstrated that olanzapine worsens motor function without improving psychosis.
...
...

References

SHOWING 1-10 OF 30 REFERENCES
Levodopa-induced psychosis: a kindling phenomenon.
TLDR
The hypothesis that chronic dopaminergic agonism may, via such a kindling mechanism, play a role in the development of some types of psychoses is supported.
Fluperlapine in tardive dyskinesia and parkinsonism
TLDR
The effects in movement disorders found in this study may imply that fluperlapine is less liable than traditional neuroleptics to induce acute extrapyramidal side effects and tardive dyskinesia and is particularly beneficial in the treatment of patients vulnerable to neurological side-effects.
Mental symptoms in Parkinson's disease during chronic treatment with levodopa
TLDR
The results suggest that the high incidence of dementia in patients with Parkinson's disease who take levodopa reflects prolongation of the course of the illness rather than a direct effect of the medication.
Pharmacology of hallucinations induced by long-term drug therapy.
TLDR
The character of the hallucinations appeared distinct from the classic description of either acute anticholinergic or acute aminergic hallucinatory states, which suggests that the dopaminergic/cholinergic systems are reciprocally active in the pathophysiology of long-term drug-induced hallucinations in this population of Parkinson's disease patients.
Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy
TLDR
Patients treated with levodopa for 4 to 8 years were significantly more impaired with parkinsonism than patients treated for 0 to 3 years, even when patients were matched for total duration of disease.
CLOZAPINE AND HALOPERIDOL IN A SINGLE‐BLIND CROSS‐OVER TRIAL: THERAPEUTIC AND BIOCHEMICAL ASPECTS IN THE TREATMENT OF SCHIZOPHRENIA
TLDR
It is suggested that haloperidol increases the turnover of brain dopamine to a greater degree than clozapine, which was found to be significantly better for the treatment of somatic concern, anxiety, conceptual disorganisation, tension and mannerism/posturing.
Exogene Psychosen beim Parkinsonsyndrom. Häufigkeit und Entstehungsbedingungen
TLDR
Prisposing factors for exogenous psychosis proved to be: a higher age at the beginning of the treatment and the initiation of treatment, a pronounced neurological symptomatology and signs of dementia as well as additional physical diseases.
Results of a multicenter AMDP study with fluperlapine in schizophrenic patients.
TLDR
In an open multicenter trial (7 hospitals) 85 schizophrenic patients were treated with 3-fluoro-6-(4-methyl-piperazinyl)- 11H -dibenz[b,e]azepine ( fluperlapine) during 20 days, causing a significant antipsychotic effect and pronounced improvement of depressive symptoms.
Treatment of advanced Parkinson disease with pergolide
Pergolide mesylate, a semisynthetic ergoline and a potent, long-acting central dopamine agonist, was tested in 13 patients with advanced Parkinson disease and diurnal oscillations in performance
Pergolide therapy for Parkinson's disease
TLDR
Pergolide mesylate, a long-acting dopamine agonist, is effective in treating Parkinson's disease and transient psychiatric or intellectual changes were similar to those seen with other dopamine agonists.
...
...